Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-18
2011-01-18
Andres, Janet L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S044000, C546S046000
Reexamination Certificate
active
07872013
ABSTRACT:
The present disclosure is directed to modulators of opiate- and/or NMDA receptors and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the use of such compounds for the treatment and/or management of pain, anxiety, neurodegeneration, drug dependence, coughing, muscular tension, and/or glaucoma and any other condition in which it is beneficial to modulate an opiate- and/or NMDA receptor.
REFERENCES:
patent: 4861598 (1989-08-01), Oshlack
patent: 4970075 (1990-11-01), Oshlack
patent: 5202128 (1993-04-01), Morella
patent: 5266331 (1993-11-01), Oshlack
patent: 5378474 (1995-01-01), Morella
patent: 5508042 (1996-04-01), Oshlack
patent: 5549912 (1996-08-01), Oshlack
patent: 5656295 (1997-08-01), Oshlack
patent: 5723147 (1998-03-01), Kim
patent: 5807572 (1998-09-01), Kim
patent: 5891467 (1999-04-01), Willis
patent: 5908927 (1999-06-01), Nguyen
patent: 5931809 (1999-08-01), Gruber
patent: 5962016 (1999-10-01), Willis
patent: 5997899 (1999-12-01), Ye
patent: 6066339 (2000-05-01), Stark
patent: 6071534 (2000-06-01), Kim
patent: 6171613 (2001-01-01), Ye
patent: 6193998 (2001-02-01), Ye
patent: 6241999 (2001-06-01), Ye
patent: 6348216 (2002-02-01), Kushla
patent: 6579985 (2003-06-01), Hill
patent: 6599531 (2003-07-01), Kushla
patent: 2002/0013372 (2002-01-01), Ekins
patent: 2007/0099947 (2007-05-01), Dean
patent: 2008/0033011 (2008-02-01), Tung
patent: 2008/0280936 (2008-11-01), Tung
patent: 2009/0076135 (2009-03-01), Czarnik
patent: 2009/0082382 (2009-03-01), Czarnik
patent: 2009/0082383 (2009-03-01), Czarnik
patent: 2009/0208413 (2009-08-01), Reis
patent: 2009/0214650 (2009-08-01), Ehrich
patent: 101398414 (2009-04-01), None
patent: 737069 (1996-10-01), None
patent: 9526325 (1995-10-01), None
patent: 2006091885 (2006-08-01), None
patent: 2006091885 (2006-08-01), None
patent: 2007056300 (2007-05-01), None
patent: 2007056300 (2007-05-01), None
patent: 2007089934 (2007-08-01), None
patent: 2007089934 (2007-08-01), None
patent: 2008022285 (2008-02-01), None
Oshlack et al, DN 132:256023, (2000).
Kolesnikov et al, DN 132:102854, (2000).
Caruso, DN 131:303399, (1999).
Elison, C.; Effect of Deuteration of N-CH3 Group on Potency and Enzymatic N-Demethylation of Morphine; Science vol. 134, (1961) p. 1078-1079.
Abe, Kaoru et. al.; Morphine alkaloids. V. Reaction mechanism of the reduction of 14.beta.-bromocodeinone with sodium borohydride; Chemical & Pharmaceutical Bulletin (1969), 17(9), 1847-53.
Bauer, LA et. al.; Influence of long-term infusions on lidocaine kinetics; Clin. Pharmacol. Ther. 1982, 433-7.
Boettcher, Chotima et. al.; How human neuroblastoma cells make morphine; Proceedings of the National Academy of Sciences of the United States of America (2005), 102(24), 8495-8500.
Borgstrom, L. et. al.; Comparative Pharmacokinetics of Unlabeled and Deuterium-Labeled Terbutaline: Demonstration of a Small Isotope Effect; J Pharm Sci, 1988, 77(11), 952-4.
Brine, GA et. al.; Formamidinesulfinic Acid Reduction of Dihydrocodeinone Derivatives; J. Org. Chem. 1978, 43(8), 1555-7.
Browne, T.R.; Chapter 2. Isotope Effect: Implications for Pharmaceutical Investigations; Pharm. Lib. 1997, 13.
Browne, T.R. et. al.; Pharmacokinetic Equivalence of Stable-Isotope-Labeled and Unlabeled Drugs. Phenobarbital in Man; J Clin Pharmacol, 1982, 22, 309-315.
Burm, AGL et. al.; Pharmacokinetics of Lidocaine and bupivacaine and stable isotope-labeled analogs: a study in healthy volunteers; Biopharmaceutics and Drug Disposition, 1988, 9, 85-95.
Edinboro, Leslie E. et. al.; Direct Analysis of Opiates in Urine by Liquid Chromatography-Tandem Mass Spectrometry; Journal of Analytical Toxicology (2005), 29(7), 704-710.
Elison, Christian et. al.; Some aspects of the fate and relation of the N-methyl group of morphine to its pharmacological activity; Journal of Medicinal Chemistry (1963), 6 237-46.
Farmer, PB et. al.; Synthesis, Metabolism, and Antitumor Activity of Deuterated Analogues of 1-(2-Choloroethyl)-3-cyclohexyl-1-nitrosourea; Journal of Medicinal Chemistry, 1978, vol. 21, No. 6, 514-20.
Fisher, MB et. al.; The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism; Curr Opin Drug Discov Develop; 2006, 9(1), 101-9.
Foster, AB; Deuterium Isotope Effects in Studies of Drug Metabolism; Trends in Pharmacological Sciences, Dec. 1984, 524-7.
Gunnar, Teemu et. al.; Validated toxicological determination of 30 drugs of abuse as optimized derivatives in oral fluid by long column fast gas chromatography/electron impact mass spectrometry; Journal of Mass Spectrometry (2005), 40(6), 739-753.
Helfenbein, J. et. al.; Isotopic Effect Study of Propofol Deuteration on the Metabolism, Activity, and Toxicity of the Anesthetic; J. Med. Chem. 2002, 45, 5806-5808.
Kushner, DJ et. al.; Pharmacological uses and perspectives of heavy water and deuterated compounds; Can J Phys Pharm 1999, 77, 79-88.
Lawson, John A. et. al.; Synthesis of morphine-d5 and codeine-d8; Journal of Heterocyclic Chemistry (1976), 13(3), 593-5.
Lee, H. et. al.; Deuterium Magic Angle Spinning Studies of Substrates Bound to Cytochrome P450; Biochemistry 1999, 38, 10808-10813.
Levisky, J.A. et. al.; The use of two different isotopic drug analogs as internal standards in the GC/MS quantitation of opiates in postmortem specimens: Demonstration of linearity with a single injection; Chem Abr vol. 140 No. 640722, (2002).
Mamada, K. et. al.; Pharmacokinetic Equivalence of Deuterium-Labeled and Unlabeled Phenytoin; Drug Metabolism and Disposition, 1986, 14(4), 509-11.
Nelson, SD et. al.; Primary and B-Secondary Deuterium Isotope Effects in N-Deethylation Reactions; Journal of Medicinal Chemistry, 1975, vol. 18, No. 11.
Nelson, SD et. al.; The Use of Deuterium Isotope Effect to Probe the Active Site Properties, Mechanism of Cytochrome P450-catalyzed Reactions, and Mechanisms of Metabolically Dependent Toxicity; Drug Metabolism and Disposition 31:1481-1498, 2003.
Osborne, N.N. et. al.; Neuroprotection in relation to retinal ischemia and relevance to glaucoma; Survey of Ophthalmology (1999), 43 Suppl 1 S102-28.
Pohl, L.R. et. al.; Determination of toxic Pathways of Metabolism by Deuterium Substitution; Drug Metabolism Rev. 1985, 1335.
Rampe, D. et al.; Deuterated Analogs of verapamil and nifedipine. Synthesis and biological activity; Eur J Med Chem (1993) 28,259-263.
Thompson, John A. et. al.; Deuterium and tritium isotope effects on the microsomal N-demethylation of ethylmorphine; Drug Metabolism and Disposition (1974), 2(6), 577-82.
Zhang, Ao et. al.; Synthesis of 2-Fluoro-11-hydroxy-N-propylnoraporphine: A Potential Dopamine D2 Agonist; Organic Letters (2005), 7(15), 3239-3242.
Bergeron, A., et al, Importance of using highly pure internal standards for successful liquid chromatography/tandem mass spectrometric bioanalytical assays, Rapid Communications in Mass Spectrometry, 2009, 23(9), 1287-97.
Gustavsson, E., Validation of direct injection electrospray LC-MS/MS for confirmation of opiates in urine drug testing, Journal of Mass Spectrometry, 2007, 42(7), 881-9.
Balikova, M.A., Hair analysis for opiates: evaluation of washing and incubation procedures, Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 789(1), 93-100.
Hackett, J., Automation of solid-phase extraction for urinary opiate analysis, American Laboratory, 2008, 40(19), 24-5.
Proksa, B., 10-Oxomorphine, A decomposition product of Morphine, Chemicke Zvesti, 1978, 32(5), 710-14.
Morphine-d3 hydrochloride, Fluka / Order No. M6380, http://www.sigmaaldrich.com/catalog/ProductDetail.do?lang=en&N4=M6380|FLUKA&N5=SEARCH—CONCAT—PNO|BRAND—KEY&F=SPEC, Nov. 24, 2009.
Morphine-D3 hydrochloride trihydrate, Shanghai FWD Chemicals Ltd. / Cat. No. M45358, http://www.fwdchem.com/show.jsp?categoryno=M45358, Scifinder Database Publication Date: Apr. 28, 2009.
7,8-Didehydro-4,5-Epoxy-17-[Methyl-D3]Morphinan-3,6-Diol Hydrochloride: Triydrate, Bepharm Ltd. / Cat. No. B110135, http://www.bepharm.com/product.jsp?id=B110135, Scifinder Database Publication Date: Mar. 10,
Gant Thomas G.
Sarshar Sepehr
Andres Janet L.
Auspex Pharmaceuticals, Inc.
Bennett Dennis A.
Covington Raymond
Sertic Michael
LandOfFree
Preparation and utility of opioid analgesics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preparation and utility of opioid analgesics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preparation and utility of opioid analgesics will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2666481